Content area
Full Text
Introduction: Triple negative breast cancer (TNBC) is one of the most aggressive subtypes of breast cancer. Due to the lack of hormone receptors, chemotherapy using taxane-adriamycin-cyclophosphamide (TAC) regimen remains the mainstay of TNBC treatment and is the only choice of treatment available for TNBC. However, TNBC is characterised by high risk of recurrence, metastasis and chemoresistance, and is associated with inter-individual variability in treatment response. Despite several mechanisms have been implicated in anticancer drug resistance, the exact mechanism of chemoresistance in TNBC remains unclear. A defective transport is a major mechanism of resistance. Transmembrane transport proteins such as breast cancer resistance protein (BCRP) encoded by ABCG2 can cause chemoresistance by means of increased efflux transportation of the drug out of the cell, hindering its...